Fenfluramine

🧮 Dose calculator

Dravet syndrome · Regimen source: FDA Fintepla · 2.2

• • With stiripentol + clobazam: max 0.2 mg/kg twice daily (17 mg/day). Strong CYP1A2/2D6 inhibitors: max 20 mg/day (17 with stiripentol). Hepatic impairment per Table 2. Echocardiogram before, every 6 months and after. FDA Fintepla · 2.2FDA Fintepla · 2.3FDA Fintepla · 2.5FDA Fintepla · 2.6

Enter age and weight.

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Fintepla · 8.1

  “Risk Summary There are no data on FINTEPLA use in pregnant women.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Fintepla · 8.2

  “Risk Summary There are no data on the presence of fenfluramine or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Fintepla · 8.4

  “The safety and effectiveness of FINTEPLA for the treatment of seizures associated with DS and LGS have been established in patients 2 years of age and older.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Fintepla · 8.5

  “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Fintepla · 8.3

  “Infertility In animal studies, oral administration of fenfluramine resulted in adverse reproductive effects in males and females at clinically relevant doses in the presence of parental toxicity [see Nonclinical Toxicology (13.1) ] .”